Edition:
United States

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

1.98USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,335
52-wk High
$7.60
52-wk Low
$1.78

Latest Key Developments (Source: Significant Developments)

Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market
Monday, 9 Apr 2018 02:04pm EDT 

April 9 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.ENTERED AGREEMENTS FOR PURCHASE OF 1.5 MLN SHARES AT $3.24375/SHARE IN REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.TO USE PROCEEDS FROM OFFERING TO FUND PRECLINICAL & CLINICAL DEVELOPMENT, OTHER RESEARCH & DEVELOPMENT ACTIVITIES, AMONG OTHERS.  Full Article

RXi Pharmaceuticals Qtrly Loss Per Share $0.84
Monday, 26 Mar 2018 04:40pm EDT 

March 26 (Reuters) - RXi Pharmaceuticals Corp ::RXI PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.RXI PHARMACEUTICALS CORP - QTRLY LOSS PER SHARE $0.84.  Full Article

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth
Tuesday, 16 Jan 2018 07:05am EST 

Jan 16 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH.RXI PHARMACEUTICALS CORP - COMPANY TO "CAPITALIZE" ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA).RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION.RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES.  Full Article

RXi Pharmaceuticals Announces Reverse Stock Split
Friday, 5 Jan 2018 12:45pm EST 

Jan 5 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10.RXI PHARMACEUTICALS CORP - REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 12:01 A.M. EASTERN TIME ON JANUARY 8, 2018.RXI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT.  Full Article

RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring
Monday, 18 Dec 2017 07:05am EST 

Dec 18 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING.RXI PHARMACEUTICALS CORP - RXI-109 MEETS SECONDARY OBJECTIVE AS IT WAS SHOWN TO BE SAFE AND WELL TOLERATED.RXI PHARMACEUTICALS CORP -RXI-109 STUDY SUCCESSFULLY MEETS PRIMARY EFFECTIVENESS OBJECTIVE WITH STATISTICALLY SIGNIFICANT OUTCOMES.RXI PHARMACEUTICALS - FULL STUDY RESULTS SHOW RXI-109 WAS SAFE, WELL TOLERATED FOR ALL DOSAGE GROUPS.  Full Article

RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​
Monday, 13 Nov 2017 07:05am EST 

Nov 13 (Reuters) - Rxi Pharmaceuticals Corp :RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​.RXi Pharmaceuticals - ‍collaborative research agreement to evaluate potential of RXi's sd-rxRNA technology platform for use in cancer treatments​.  Full Article

RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights
Wednesday, 8 Nov 2017 07:05am EST 

Nov 8 (Reuters) - RXi Pharmaceuticals Corp ::Reports third quarter 2017 financial results and recent corporate highlights.At September 30, 2017, company had cash of $5.4 million, compared with $12.9 million at December 31, 2016​.Qtrly loss per share $0.11​.  Full Article

RXi Pharma announces completion of enrollment of phase 2 clinical trial
Wednesday, 6 Sep 2017 07:05am EDT 

Sept 6 (Reuters) - RXi Pharmaceuticals Corp ::RXi Pharmaceuticals announces completion of enrollment of phase 2 clinical trial with samcyprone for cutaneous warts.  Full Article

RXi Pharmaceuticals files for sale of up to 7.3 mln shares
Friday, 18 Aug 2017 05:44pm EDT 

Aug 18 (Reuters) - RXi Pharmaceuticals Corp ::RXi Pharmaceuticals Corp- files for sale of up to 7.3 million shares of common stock by Lincoln Park Capital Fund Llc - SEC filing‍​.  Full Article

RXi Pharmaceuticals Corp reports Q2 loss per share $0.11‍​
Thursday, 10 Aug 2017 07:05am EDT 

Aug 10 (Reuters) - RXi Pharmaceuticals Corp :RXi Pharmaceuticals reports second quarter 2017 financial results and recent corporate highlights.RXi Pharma - existing cash, potential proceeds available under equity facility with lpc should be sufficient to fund operations for at least next 12 months​.RXi Pharmaceuticals Corp qtrly loss per share $0.11‍​.  Full Article

BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS